Navigation Links
Next Safety Releases Advanced Respirator for Infectious Diseases
Date:8/5/2009

/p>

Next Safety is also developing other pulmonary drug delivery platforms for inhaled antibiotics and anti-medics, concentrated narcotics and drugs to treat pulmonary conditions such as asthma, COPD and the immune compromised.

The doctors, scientists and engineers who work for Next Safety have developed the most comprehensive and effective solution for the pulmonary delivery of medicines to in-home patients and persons who are addicted to smoking cigarettes. The company is developing combined respirator and pulmonary drug delivery systems for soldiers to have highly sophisticated medical care that greatly enhances their likely hood of survival in battle.

Next Safety engineers are experts in high-volume manufacturing. The company's engineers and managers have made more than 40 million electrical devices a month for years. These are products that are designed to protect babies and children.

Next Safety has invested in significant capacity for pandemic stockpiling. The company expects to build approximately 5 million respirators for delivery in December 2009 and has the capacity to build 300 million respirators a month for pandemic stockpiling by March 2010.

Next Safety thanks the doctors and staff at Italy's level-4 Milan biological research center for helping it design the best respirators for pandemic stockpiling.

Next Safety's advanced respirator product line is available at http://www.nextsafety.com. 

    Contact:

    Eric Hunter
    336-246-7700
   http://www.nextsafety.com

This release was issued through eReleases(TM). For more information, visit '/>"/>

SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
2. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements
6. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
7. iCardiac Selected for Multiple Cardiac Safety Studies
8. Assessment of safety and efficacy of human embryonic stem cell therapy
9. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., BLOOMINGTON, Minn., Nov. 30 Ac...dical image management software, data migration to... Allina Hospitals and Clinics for a new Vendor Neu...age storage across the Allina network of hospitals...tion is based on the Acuo Technologies DICOM Servi...
(Date:11/30/2009)... , BRIARCLIFF MANOR, N.Y., Nov. 30 /PRNewsw...guidance document for the publication of company-s...ne today by the British Medical Journal (BMJ). "Th... of the importance of providing support and guidan...tion of study results in the peer-reviewed medical...
(Date:11/30/2009)... , CHANGCHUN, China and LOS ANGELES, Nov. ...armaceuticals, Inc. (OTC Bulletin Board: CYXN; ,Ch...leading manufacturer, distributor and,retailer of ...nced it has,completed preparation for distribution... The Chinese government recently formalized the ...
(Date:11/30/2009)... PDS, a leader in providing smart...ty, announces Pajama Pathology®, evolutionizin...ame ‘gold standard’ software used by 8...ld, but on a ‘cost per slide’ basis. ...EB) November 30, 2009 -- PDS has announced another...
Breaking Biology Technology:Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 2Pajama Pathology -- the New Wave of Preclinical Pathology Embraced by PDS 3
...Nasdaq: PARS ) today reported results for the sec...ed a net loss of $2.7 million, or $0.10 per share,... of $4.6 million, or,$0.18 per share, in the secon...$9.0 million at June 30, 2008., The decrease in n...ly,to a 46% decrease in operating expenses to $2.6...
...ion,(Nasdaq: VRNM ), a leading developer of cellu...lopment of high-performance specialty enzymes, ann...ice President, will present at,the upcoming Canacc...e,presentation is scheduled to begin at 10:30 a.m....the InterContinental Hotel in Boston., More infor...
...unches Should Contribute Significantly in Second H...ical Companies, Inc. (NYSE: PRX ) today announced...8., Second Quarter and Six Month Results, For th... total revenues,of $112.9 million and a net loss o...is compared with reported revenues of $167.6 and n...
Other Biology Technology:Pharmos Corporation Reports 2008 Second Quarter Results 2Pharmos Corporation Reports 2008 Second Quarter Results 3Pharmos Corporation Reports 2008 Second Quarter Results 4Pharmos Corporation Reports 2008 Second Quarter Results 5Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 2Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference 3Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8
(Date:11/30/2009)...N Clemson University researchers Ron Falta and La...l Protection Agency grant to study the safe storag...ed deep below the earth,s surface. , With carbon...ved to be the leading cause of global warming, geo...ing alternatives for reducing emissions using curr...
(Date:11/30/2009)...(Nov. 30, 2009) Scientists and engineers from two...energy will come together Dec. 7 with leading aca...nd pumping blood. , Much like moving oil through... body. Both systems need clean, well-functioning ...rosion, to function efficiently. Both industries a...
(Date:11/30/2009)...antage of lower early bird registration rates and ...congress of 2010 at http://www.iofwco-ecceo10.org...of the International Osteoporosis Foundation (IOF)...c Aspects of Osteoporosis and Osteoarthritis (ESCE...orld are expected to attend. The exciting scientif...
Breaking Biology News(10 mins):Similarities of pumping blood and oil examined 2Similarities of pumping blood and oil examined 3MDC scientists show how hematopoietic stem cell development is regulated 10272 1MDC scientists show how hematopoietic stem cell development is regulated 10272 2NIDCR launches the FaceBase Consortium 10269 1NIDCR launches the FaceBase Consortium 10269 2NIDCR launches the FaceBase Consortium 10269 3NIDCR launches the FaceBase Consortium 10269 4NIDCR launches the FaceBase Consortium 10269 585 25 of People Would Consider Medical Tourism 58945 185 25 of People Would Consider Medical Tourism 58945 285 25 of People Would Consider Medical Tourism 58945 3
...lumbia University announces today that it recently...t generation DNA sequencing technology to Intellig...quencing technology was invented by Dr. Jingyue Ju...A Sequencing and Chemical Biology at the Judith P....ia University. The fundamentals of this new techno...
...relin, a hormone produced in the stomach, induces ...at controls cravings for food and other energy sou...t in the October 19 online issue of The Journal of...associated with growth hormone release, appetite, ...the reward circuitry of the brain that regulates f...
...ute lung injury caused by cell death, high and pot...), and the resulting excess fluid in the lungs (pu...vels of the angiopoietin2 (Ang2) protein, research...ber 5 online issue of Nature Medicine. , The study...author Jack Elias, M.D., the Waldemar Von Zedtwitz...
Other Biology News:Columbia University licenses next-generation DNA sequencing technology 2Key to acute lung injury lies in Ang2 protein 2
...eal CO2 incubator for cell and tissue cultures, in...ody temperature. HERAcell incubators are specifica...ct and grow your valuable samples: , , Safe and s... growth. , ContraCon 90 C decontamination routine...
...ort Mass Directed Auto Purification software, a we...signed for automated compound isolation and purifi...covery programs. The system has been designed spec... auto purification for synthetic chemists using a ...
...antibody was derived from rabbit immunized with hi...inant protein domains such as antibody fragments c... on phage using phagemid-based systems (1), rather... libraries. Anti-M13 pIII Monoclonal Antibody can ...
Rapid DNA Ligation Kit from Roche Applied Science
Biology Products: